ROLE OF NANOTECHNOLOGY IN CANCER THERAPY AND DIAGNOSIS

In the recent times nanotechnological innovations have been applied extensively in finding solutions to problems encountered during conventional cancer therapy and diagnosis- mainly catering to drug targeting and minimizing concomitant adverse effects. From the first studies on liposome-encapsulated drug nanoparticles, progressing through PEGylation to incorporation of biomarkers on the surface, the field has continuously evolved to accommodate newer technologies like gene therapy using Rexin-G, delivering silencing RNA by "Trojan horse" approach to the tumour cells, thermal destruction of the cancerous cells using Kanzius machine and gold nanoparticles. On similar lines, semiconductor-stuffed nanoparticles called quantum dots have improved cancer detection by leaps and bounds. The field of nanotechnology continues to excite the researchers for its immense and untapped utility towards cancer therapy and diagnosis, as witnessed in form of undertrial projects like the formulation of novel BIND-014 nanoparticle, cyclodextrin-based nanoparticle, chemically engineered adenovirus-nanoparticle for stimulating the immune system and another one used as a magnetic resonance imaging contrast agent, among others. Commercialization of recyclable, microemulsion-based nanoparticles is still underway, which could possibly be a significant step towards eco-friendliness and cost

[1]  S. Bhatia,et al.  Multifunctional Nanoparticles for Cancer Therapy , 2006 .

[2]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[3]  Samuel Zalipsky,et al.  Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. , 2004, Advanced drug delivery reviews.

[4]  P. Couvreur,et al.  Design of folic acid-conjugated nanoparticles for drug targeting. , 2000, Journal of pharmaceutical sciences.

[5]  A. Escargueil,et al.  Resistance mechanisms associated with altered intracellular distribution of anticancer agents. , 2000, Pharmacology & therapeutics.

[6]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[7]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Barratt,et al.  Colloidal drug carriers: achievements and perspectives , 2003, Cellular and Molecular Life Sciences CMLS.

[9]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[10]  S. Hockfield,et al.  Glial Tumor Invasion: A Role for the Upregulation and Cleavage of BEHAB/Brevican , 2001, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[11]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Susan M. Chang,et al.  Current Chemotherapy for Glioblastoma , 2003, Cancer journal.

[13]  P. Gutin,et al.  Neuro-oncology: diagnosis and management of cerebral gliomas--past, present, and future. , 2000, Neurosurgery.

[14]  M. Ferrari Nanovector therapeutics. , 2005, Current opinion in chemical biology.

[15]  R. Barth A critical assessment of boron neutron capture therapy: an overview , 2003, Journal of Neuro-Oncology.

[16]  Z. Tökés,et al.  Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. , 1983, Cancer research.

[17]  P. Couvreur,et al.  Increased bone marrow toxicity of doxorubicin bound to nanoparticles. , 1994, European journal of cancer.

[18]  H. Dai,et al.  Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[20]  James F Rusling,et al.  Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. , 2009, ACS nano.

[21]  Zhuang Liu,et al.  Drug delivery with carbon nanotubes for in vivo cancer treatment. , 2008, Cancer research.

[22]  Seymour,et al.  Control of tumour vascular permeability. , 1998, Advanced drug delivery reviews.

[23]  M. Ferrari Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[24]  R. Müller,et al.  Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. , 1987, Biomaterials.

[25]  P. Ajayan,et al.  Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation , 2009, Proceedings of the National Academy of Sciences.

[26]  M. Westphal,et al.  Dissecting glioma invasion: interrelation of adhesion, migration and intercellular contacts determine the invasive phenotype , 1999, International Journal of Developmental Neuroscience.

[27]  Vladimir P Torchilin,et al.  Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. , 2002, Cancer research.

[28]  P Couvreur,et al.  Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Gert Storm,et al.  Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system , 1995 .

[30]  V. Ferrans,et al.  Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. , 1990, Journal of the National Cancer Institute.

[31]  Multi-functional nanoparticles for cancer therapy , 2007 .

[32]  M. Berger Malignant astrocytomas: surgical aspects. , 1994, Seminars in oncology.